Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 7 of 7 citing Greenbaum: Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment.... (0.05 sec) 

GAD treatment and insulin secretion in recent-onset type 1 diabetes


J Ludvigsson, M Faresjo, M Hjorth, S … - The New England journal of medicine, 2008 - nejm.highwire.org
Results Insulin secretion gradually decreased in both study groups. The study
treatment had no significant effect on change in fasting C-peptide level after
15 months (the primary end point). Fasting C-peptide levels declined from ...
Cited by 32 - Related articles - All 7 versions

Therapy with GAD in diabetes


J Ludvigsson - Diabetes/Metabolism Research and Reviews, 2009 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ...
Related articles - All 2 versions

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb …


KC Herold, S Gitelman, C Greenbaum, J Puck, … - Clinical Immunology, 2009 - Elsevier
Anti-CD3 mAbs may prolong β cell function up to 2 years in patients with new
onset Type 1 diabetes (T1DM). A randomized open label trial of anti-CD3 mAb,
Teplizumab, in T1DM was stopped after 10 subjects because of increased ...
Cited by 2 - Related articles - All 2 versions

[CITATION] Challenges in developing endpoints for type 1 diabetes intervention studies Updated …


S Cernea, I Raz, KC Herold, B Hirshberg, BO … - Diabetes/Metabolism Research and Reviews, 2009 - John Wiley & Sons, Ltd. Chichester, UK

Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of …


… , B Keymeulen, K Decochez, I Weets, C De … - Diabetologia - Springer
Abstract Aims/hypothesis The aim of the study was to investigate the use of
hyperglycaemic clamp tests to identify individuals who will develop diabetes
among insulinoma-associated protein-2 antibody (IA-2A)-positive ...

[CITATION] C-peptide an adequate endpoint in type 1 diabetes


J Ludvigsson - Diabetes/Metabolism Reviews - interscience.wiley.com
It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ...

Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet …


KM Dungan, JB Buse, RE Ratner - Diabetes/Metabolism Research and Reviews, 2009 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ...
Related articles - All 2 versions


 


Go to Google Home - About Google - About Google Scholar

©2009 Google